These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29437790)

  • 21.
    Pool M; Terwisscha van Scheltinga AGT; Kol A; Giesen D; de Vries EGE; Lub-de Hooge MN
    Eur J Nucl Med Mol Imaging; 2017 Aug; 44(8):1328-1336. PubMed ID: 28315949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma.
    Gaspar N; Sharp SY; Eccles SA; Gowan S; Popov S; Jones C; Pearson A; Vassal G; Workman P
    Mol Cancer Ther; 2010 May; 9(5):1219-33. PubMed ID: 20457619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells.
    Choi YJ; Kim SY; So KS; Baek IJ; Kim WS; Choi SH; Lee JC; Bivona TG; Rho JK; Choi CM
    PLoS One; 2015; 10(3):e0119832. PubMed ID: 25780909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a radiocobalt-labelled affibody molecule for imaging of human epidermal growth factor receptor 3 expression.
    Rosestedt M; Andersson KG; Mitran B; Rinne SS; Tolmachev V; Löfblom J; Orlova A; Ståhl S
    Int J Oncol; 2017 Dec; 51(6):1765-1774. PubMed ID: 29039474
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HSP90 inhibitor AUY922 can reverse Fulvestrant induced feedback reaction in human breast cancer cells.
    Bai J; Zhou G; Qiu Y; Hu Y; Liu J; Zhao J; Zhang S; Zhang J
    Cancer Sci; 2017 Jun; 108(6):1177-1184. PubMed ID: 28301080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 2-phenylethynesulphonamide (PFT-μ) enhances the anticancer effect of the novel hsp90 inhibitor NVP-AUY922 in melanoma, by reducing GSH levels.
    Yeramian A; Vea A; Benítez S; Ribera J; Domingo M; Santacana M; Martinez M; Maiques O; Valls J; Dolcet X; Vilella R; Cabiscol E; Matias-Guiu X; Marti RM
    Pigment Cell Melanoma Res; 2016 May; 29(3):352-71. PubMed ID: 26988132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of Hsp90 augments docetaxel therapy in castrate resistant prostate cancer.
    Ku S; Lasorsa E; Adelaiye R; Ramakrishnan S; Ellis L; Pili R
    PLoS One; 2014; 9(7):e103680. PubMed ID: 25072314
    [TBL] [Abstract][Full Text] [Related]  

  • 28.
    Pool M; Kol A; de Jong S; de Vries EGE; Lub-de Hooge MN; Terwisscha van Scheltinga AGT
    MAbs; 2017; 9(8):1370-1378. PubMed ID: 28873009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting HSP90 with the small molecule inhibitor AUY922 (luminespib) as a treatment strategy against hepatocellular carcinoma.
    Augello G; Emma MR; Cusimano A; Azzolina A; Mongiovì S; Puleio R; Cassata G; Gulino A; Belmonte B; Gramignoli R; Strom SC; McCubrey JA; Montalto G; Cervello M
    Int J Cancer; 2019 May; 144(10):2613-2624. PubMed ID: 30488605
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chaperone-mediated autophagy degradation of IGF-1Rβ induced by NVP-AUY922 in pancreatic cancer.
    Xue N; Lai F; Du T; Ji M; Liu D; Yan C; Zhang S; Yu X; Jin J; Chen X
    Cell Mol Life Sci; 2019 Sep; 76(17):3433-3447. PubMed ID: 30980109
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage.
    Zaidi S; McLaughlin M; Bhide SA; Eccles SA; Workman P; Nutting CM; Huddart RA; Harrington KJ
    PLoS One; 2012; 7(4):e35436. PubMed ID: 22523597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bioluminescence Imaging to Monitor the Effects of the Hsp90 Inhibitor NVP-AUY922 on NF-κB Pathway in Endometrial Cancer.
    Yeramian A; García V; Bergadà L; Domingo M; Santacana M; Valls J; Martinez-Alonso M; Carceller JA; Cussac AL; Dolcet X; Matias-Guiu X
    Mol Imaging Biol; 2016 Aug; 18(4):545-56. PubMed ID: 26604096
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ImmunoPET and biodistribution with human epidermal growth factor receptor 3 targeting antibody ⁸⁹Zr-RG7116.
    Terwisscha van Scheltinga AG; Lub-de Hooge MN; Abiraj K; Schröder CP; Pot L; Bossenmaier B; Thomas M; Hölzlwimmer G; Friess T; Kosterink JG; de Vries EG
    MAbs; 2014; 6(4):1051-8. PubMed ID: 24870719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Affibody-mediated PET imaging of HER3 expression in malignant tumours.
    Rosestedt M; Andersson KG; Mitran B; Tolmachev V; Löfblom J; Orlova A; Ståhl S
    Sci Rep; 2015 Oct; 5():15226. PubMed ID: 26477646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical Study of AUY922, a Novel Hsp90 Inhibitor, in the Treatment of Esophageal Adenocarcinoma.
    Kosovec JE; Zaidi AH; Kelly LA; Rotoloni CL; Vytlacil C; DiCarlo C; Matsui D; Komatsu Y; Boyd NH; Omstead A; Kolano EL; Biederman RW; Finley G; Silverman JF; Landreneau RJ; Jobe BA
    Ann Surg; 2016 Aug; 264(2):297-304. PubMed ID: 26445473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BAG3-dependent expression of Mcl-1 confers resistance of mutant KRAS colon cancer cells to the HSP90 inhibitor AUY922.
    Wang CY; Guo ST; Croft A; Yan XG; Jin L; Zhang XD; Jiang CC
    Mol Carcinog; 2018 Feb; 57(2):284-294. PubMed ID: 29068469
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Low dose HSP90 inhibition with AUY922 blunts rapid evolution of metastatic and drug resistant phenotypes induced by TGF-β and paclitaxel in A549 cells.
    Bacon NA; Larre I; Lawag AA; Merritt C; Smith M; Rosolen M; Sollars VE
    Biomed Pharmacother; 2020 Sep; 129():110434. PubMed ID: 32768937
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hsp90 inhibition by AUY922 as an effective treatment strategy against myxoid liposarcoma.
    Steinmann S; Gali-Muhtasib H; Huebner K; Al-Halabi R; Abou Merhi R; Aman P; Agaimy A; Haller F; Schneider-Stock R
    Cancer Lett; 2015 Oct; 367(2):147-56. PubMed ID: 26225840
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
    Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
    Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.